netFormulary NHS
Nottinghamshire Area Prescribing Committee
Joint Formulary
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
For patient information about chemotherapy and chemotherapy regimens, please see the Macmillan cancer support website: 
Chapter Links...
 Details...
08.01.02  Expand sub section  Anthracyclines and other cytotoxic antibiotics
Cytotoxic Drug Doxorubicin
View adult BNF View SPC online View childrens BNF
Formulary
Red

Injection

 
Link  NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
   
Cytotoxic Drug Pegylated-liposomal doxorubicin (Caelyx®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Concentrate for intravenous infusion

  • Approved in line with NICE TA389 for treating recurrent ovarian cancer.
    NB: Trabectedin in combination with pegylated liposomal doxorubicin is not recommended for treatment of the first recurrence of platinum-sensitive ovarian cancer.
    Also approved in accordance with the National Cancer Drugs Fund List for the treatment of certain named sarcomas.
    NUH: For more information, including criteria, see the DTC website; available here. Confirm funding approved on BlueTeq for all new starters.
    SFH: Confirm funding by contacting the HCD Team on 4660
 
Link  Link to reviews
Link  MHRA: Liposomal and lipid-complex formulations: name change to reduce medication errors
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Cytotoxic Drug Bleomycin
View adult BNF View SPC online View childrens BNF
Formulary
Red
Injection 
Link  Link to reviews
   
Cytotoxic Drug Dactinomycin (Cosmegen Lyovac®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Injection- NUH only 
Link  Link to reviews
   
Cytotoxic Drug Daunorubicin
View adult BNF View SPC online View childrens BNF
Formulary
Red
Injection 
   
Cytotoxic Drug Epirubicin
View adult BNF View SPC online View childrens BNF
Formulary
Red
Injection 
   
Cytotoxic Drug Idarubicin (Zavedos®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Caspule, Injection- NUH only 
Link  SFH: Idarubicin-Dex (Z-DEx) in Myeloma and Palliative Lymphoma
   
Liposomal Cytarabine-Daunorubicin (Vyxeos®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Infusion

Available at NUH only: Approved in accordance with the Cancer Drugs Fund and NICE TA552 (expected entry in to baseline commissioning from 19th March 2019) for untreated acute myeloid leukaemia.

 
Link  NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
   
Cytotoxic Drug Mitomycin
(injection, bladder)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  SFH: Mitomycin and BCG (Oncotice) information for bladder cancer
   
Cytotoxic Drug Mitoxantrone (Mitozantrone)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Infusion 
   
Cytotoxic Drug Pixantrone
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

Infusion

  • For non-Hodgkins B cell lymphoma as per NICE TA306
 
Link  Link to reviews
Link  TA306:Pixantrone monotherapy
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Grey

Grey / Non-Formulary: Medicines, which the Nottinghamshire APC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.
Grey / Non-Formulary (undergoing assessment): Work is ongoing and will be reviewed at a future APC meeting.
Grey / Non-Formulary (no formal assessment): APC has not formally reviewed this medicine or indication because it had never been requested for formulary inclusion. Often used for drugs new to market.
  

Red

Medicines which should normally be prescribed by specialists only. eg hospital only.
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
  

Amber 1

Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol, once the patient has been stabilised.
Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the Nottinghamshire APC.
  

Amber 2

Medicines suitable to be prescribed in primary care / general practice after specialist* recommendation or initiation.
A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust DTCs and approved by the Nottinghamshire APC.
*Specialist is defined by the APC as a clinician who has undertaken an appropriate formal qualification or recognised training programme within the described area of practice
  

Amber 3

Primary care/ non specialist may initiate as per APC guideline.
The supporting prescribing guideline must have been agreed by the relevant secondary care trust D&TC(s) and approved by the Nottinghamshire APC.
  

Green

Medicines suitable for routine use within primary care.
Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.   

OTC

  

netFormulary